Brittany Cote

Articles

Patient-Derived Organoids Show Promise for Personalized Therapy in Pancreatic Cancer

May 5th 2020

Manuel Hidalgo Medina, MD, PhD, discusses some of the research he presented at the 2020 ACCR Virtual Annual Meeting and future areas of exciting efforts being made in pancreatic cancer.

IMRT Improves Patient-Reported Outcomes in Cervical and Endometrial Cancer

May 4th 2020

A reduction in patient-reported symptomatic adverse events was observed with intensity-modulated radiotherapy compared with standard radiotherapy in patients with cervical or endometrial cancer, whereas no difference was observed with regard to clinician-reported AEs.

Neoadjuvant Nivolumab Shows Strong Clinical Activity in Merkel Cell Carcinoma

May 4th 2020

Nivolumab, when administered approximately 4 weeks prior to surgery in patients with Merkel cell carcinoma, was found to be tolerable and to induce pathological complete responses and radiographic tumor regressions.

MRI-Targeted and Systematic Biopsy Combo Enhances Diagnostic Accuracy in Prostate Cancer

May 1st 2020

The combination of MRI-targeted and systemic biopsy led to increased detection of all prostate cancers in patients with MRI-visible lesions.

Pexidartinib Shakes Up TGCT Treatment, But Questions Remain

April 26th 2020

John A. Abraham, MD, FACS, discusses the role of surgery in the treatment of tenosynovial giant cell tumor, key challenges faced in this space, and the emergence of pexidartinib.

Sipuleucel-T Plus Radium-223 Improves Clinical Outcomes in Bone-Metastatic CRPC

April 24th 2020

Emmanuel S. Antonarakis, MBBCh, discusses the efficacy of radium-223 plus sipuleucel-T in patients with bone-metastatic castration-resistant prostate cancer and the next steps for research for this combination.

Desai Discusses COVID-19 Risk Among Patients With Cancer

April 24th 2020

Aakash Desai, MD, MPH. provides additional insight into his research on COVID-19 risk and patients with cancer and sheds light on how institutions are taking action against the virus.

Expert Highlights Novel Agents in Acute GVHD

April 23rd 2020

Mark A. Schroeder, MD, discusses emerging therapeutic strategies for patients with acute GVHD.

Novel Off-the-Shelf CAR-NK Therapy FT596 Shows Early Promise in B-Cell Malignancies

April 22nd 2020

Bob Valamehr, PhD, discusses the process by which a targeted CAR natural-killer cell product is engineered as well as how it will be examined in future research efforts.

ctDNA Identifies Acquired Resistance Mechanisms to Savolitinib in MET+ Gastric Cancer

April 21st 2020

The use of circulating tumor DNA via baseline tumor tissue or rebiopsy led to the identification of several MET mutations previously unidentified upon progression on savolitinib in patients with gastric cancer, as well as MET amplifications as drivers of resistance to the agent during monotherapy treatment of those with MET-amplified disease.

HCC Armamentarium Expands, But Sequencing and Immunotherapy Issues Remain

April 20th 2020

Ryan W. Huey, MD, highlights the evolving treatment options in the hepatocellular carcinoma paradigm and discusses challenges and next steps in the field.

Mato Highlights Promise of Investigational Immunotherapeutics in CLL

April 16th 2020

Anthony R. Mato, MD, MSCE, discusses the different research efforts that are being made with immunotherapy in chronic lymphocytic leukemia.

Multidisciplinary Care to Provide Best Possible Outcomes in HCC

April 15th 2020

Amit Singal, MD, MS, discussess optimal models for multidisciplinary care in hepatocellular carcinoma in light of the practice-changing IMbrave150 trial.

Liquid Biopsy Detects Alterations That Confer Resistance to Alpelisib in HR+ Breast Cancer

April 15th 2020

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors in patients with hormone receptor–positive metastatic breast cancer.

Amplicon-Based Liquid Biopsy Detects ALK/ROS1 Fusion and Resistance Mutations in NSCLC

April 13th 2020

Amplicon-based liquid biopsy can detect ALK/ROS1 fusions in TKI-naïve patients with non–small cell lung cancer and allows for the identification of resistance mutations in those treated with TKIs.

Ivosidenib Shows Durable Disease Control in Advanced IDH1-Mutant Chondrosarcoma

April 10th 2020

Ivosidenib showed minimal toxicity, substantial 2-hydroxyglutarate reduction, and durable disease control in patients with chondrosarcoma, a rare primary malignancy of the bone.

Indigenous American Ancestry May Be Associated With Increased Incidence of HER2+ Breast Cancer

April 9th 2020

An increased proportion of Indigenous American genetic ancestry may be linked with a higher incidence of HER2-positive breast cancer.

Pazopanib Plus Oral Cyclophosphamide Shows Benefit in Platinum-Resistant Epithelial Ovarian Cancer

April 9th 2020

Pazopanib plus oral cyclophosphamide is a well-tolerated regimen that has clinically relevant benefit in patients with platinum-resistant or -refractory epithelial ovarian cancer, according to results from a retrospective study published in the Journal of Clinical Oncology.

Expert Highlights Breakthroughs and Next Steps in RCC Paradigm

April 2nd 2020

Matthew T. Campbell, MD, discusses the evolving treatment options in the renal cell carcinoma paradigm.

Debate Continues on Optimal Neoadjuvant Regimen in Resectable Pancreatic Cancer

April 2nd 2020

Michael A. Choti, MD, MBA, FACS, discusses the role of radiation therapy in neoadjuvant therapy for resectable pancreatic cancer, the many benefits of neoadjuvant therapy over up-front surgery, and minimally invasive surgical procedures that are coming to the forefront in this disease.